Vaishali Pharma (VAISHALI) Q1 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended June 30, 2024, and the annual report for FY 2023-24.

• 17th Annual General Meeting scheduled for September 27, 2024.

• Appointed HD & Associates as Scrutinizer for e-voting and as Secretarial Auditor for FY 2024-25.

Financial highlights

• Revenue from operations for Q1 FY25 was ₹1,807.98 lakhs, up from ₹1,342.27 lakhs in Q1 FY24 and down from ₹3,239.60 lakhs in Q4 FY24.

• Net profit for Q1 FY25 was ₹169.90 lakhs, compared to ₹158.59 lakhs in Q1 FY24 and a net loss of ₹468.25 lakhs in Q4 FY24.

• Total expenses for Q1 FY25 were ₹1,623.41 lakhs, up from ₹1,166.43 lakhs in Q1 FY24 and down from ₹3,971.78 lakhs in Q4 FY24.

• Basic EPS for Q1 FY25 was ₹1.48, compared to ₹1.50 in Q1 FY24 and negative ₹4.37 in Q4 FY24.

Key financial ratios and metrics

• Gross margin improved year-over-year as revenue growth outpaced expense increases.

• Paid-up equity share capital increased to ₹1,209.42 lakhs after conversion of 13,75,000 share warrants.